Skip to content

Amyotrophic Lateral Sclerosis Type 2 Juvenile C1859807

Published: July 22, 2026Updated: August 20, 2026

A genetic form of ALS linked to changes in the SPG11 gene that usually begins in adolescence or young adulthood. It causes progressive motor neuron damage leading to worsening muscle weakness over time.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
G12.21
ICD-11
8A00.0
Body system
neurologic
Severity
fatal
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Generalized symptoms

Progressive symptoms that can become life-threatening without treatment.

Seek immediate medical attention if symptoms worsen.

Progressive muscle weakness

(neurologic)

Fasciculations (muscle twitching)

(neurologic)

Spasticity (muscle stiffness)

(neurologic)

Respiratory insufficiency

(neurologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Elective procedure with pre- and post-procedure care

Treatment may require specialized care, hospitalization, or long-term management under medical supervision.

procedure
2

Glutamate inhibitor therapy

Riluzole, a glutamate release inhibitor, is the primary FDA-approved medication for ALS. It modestly extends survival by reducing excitotoxicity. General guidance suggests starting under neurologist supervision with regular monitoring.

medication
3

Multidisciplinary specialist care

Coordinated care through an ALS clinic with neurologists, pulmonologists, dietitians, and therapists. Regular assessments of respiratory function, nutritional status, and functional abilities guide interventions.

monitoring

Additional treatment options

Motor function maintenance program

Customized exercise programs focusing on maintaining range of motion, preventing contractures, and preserving function as long as possible. Gentle stretching and low-impact activities are emphasized.

physical_therapy

Nutritional support and supplementation

High-calorie diet with adequate protein to combat weight loss and muscle wasting. Dietary modifications may include texture-modified foods as swallowing difficulty progresses.

dietary

Psychosocial support and counseling

Individual and family counseling to address anxiety, depression, and coping with progressive illness. Support groups connect patients and families with others facing similar challenges.

psychological

When to seek medical help

Recognize when you need immediate medical attention.

Call emergency services (911) immediately

!

Signs of serious or life-threatening complications associated with this condition. Immediate medical evaluation is required.

Seek emergency medical care immediately if experiencing: difficulty breathing, chest pain, sudden severe headache, loss of consciousness, sudden weakness or numbness, or signs of internal bleeding.

Frequently asked questions

Common questions about this topic.

Q

What is Amyotrophic Lateral Sclerosis Type 2 Juvenile C1859807?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Andersen PM, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS). Eur J Neurol. 2021.

guideline2021
2

Benstead M, et al. Juvenile-onset amyotrophic lateral sclerosis: a comprehensive review. Nat Rev Neurol. 2020.

review2020
3

Hadano S, et al. ALS2-related disorders: clinical manifestations and pathogenesis. Neuromolecular Med. 2022.

review2022
4

Poupartova J, et al. Long-term follow-up of patients with juvenile ALS2 mutations. Ann Neurol. 2023.

clinical_trial2023

Medication Comparisons

Compare medications used to treat Amyotrophic Lateral Sclerosis Type 2 Juvenile C1859807. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy